Discovery of (1R,2R)-N-(4-(6-isopropylpyridin-2-yl)-3-(2-methyl-2H-indazol-5-yl)isothiazol-5-yl)-2-methylcyclopropanecarboxamide, a potent and orally efficacious mGlu5 receptor negative allosteric modulator
作者:Junliang Hao、Veronique Dehlinger、Adam M. Fivush、Helene C.E. Rudyk、Thomas C. Britton、Sean P. Hollinshead、Benjamin P. Vokits、Barry P. Clark、Steven S. Henry、Steven M. Massey、Langu Peng、Bruce A. Dressman、Beverly A. Heinz、Edda F. Roberts、Mallorie R. Bracey-Walker、Steven Swanson、John T. Catlow、Patrick L. Love、Anita D. Tepool、Steven C. Peters、Rosa Maria A. Simmons、Smriti Iyengar、David L. McKinzie、James A. Monn
DOI:10.1016/j.bmcl.2013.01.009
日期:2013.3
A novel series of selective negative allosteric modulators (NAMs) for metabotropic glutamate receptor 5 (mGlu5) was discovered from an isothiazole scaffold. One compound of this series, (1R,2R)-N-(4-(6-isopropylpyridin-2-yl)-3-(2-methyl-2H-indazol-5-yl)isothiazol-5-yl)-2-methylcyclopropanecarboxamide (24), demonstrated satisfactory pharmacokinetic properties and, following oral dosing in rats, produced dose-dependent and long-lasting mGlu5 receptor occupancy. Consistent with the hypothesis that blockade of mGlu5 receptors will produce analgesic effects in mammals, compound 24 produced a dose-dependent reduction in paw licking responses in the formalin model of persistent pain. (c) 2013 Elsevier Ltd. All rights reserved.